Abbott Unveils Alinity, its Unified Family of Innovative Next-Generation Diagnostics Systems

Alinity will help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment.

PRESS RELEASE


Abbott (No. 14 on the DiversityInc Top 50 Companies for Diversity list) announced the introduction of Alinity™, its harmonized family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics. Each Alinity platform will include a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment.

Diagnostic testing guides 70 percent of health care decisions. Global testing volumes are rising due to an aging population, the growing management of chronic diseases and increased access to care. At the same time, health systems are facing pressures to perform testing as efficiently as possible with limited staff and space while also reducing costs. Many institutions and labs use multiple diagnostic platforms, often within a larger health care network. As they serve more patients and try to improve service levels with fewer qualified technicians, institutions are looking for new technologies that can help maximize testing efficiencies and help better manage resources.

Designed with universal, intuitive interfaces as well as common software and hardware, Abbott's Alinity systems will have the ability to work together, providing greater capacity and simplifying the user experience. Several of the platforms will be designed to run more tests in less space, generate test results faster and minimize human errors. By offering a comprehensive solution that addresses the challenges of using multiple diagnostics platforms, while continuing to provide quality results that positively impact patient care, Alinity could potentially change the industry's testing paradigm.

"Abbott's Alinity portfolio is unprecedented in the industry," said Brian Blaser, executive vice president, Diagnostics Products, Abbott. "With our unified family of testing instruments, we'll be able to offer more efficiency, flexibility and confidence to health systems and better help doctors and nurses get the results they need to improve decision-making and patient care."

Abbott expects Alinity launches to begin later this year and continue into 2017.1 The systems are supported by Abbott's AlinIQ™, the first-of-its-kind, combined professional services and informatics solution that assists labs in achieving greater operational productivity with their existing resources. AlinIQ launched worldwide in April 2016.

DEVELOPED WITH CUSTOMER NEEDS IN MIND

To develop each next-generation platform, Abbott's research and development teams engaged with thousands of clinicians, scientists, lab technicians and health care executives. The goal was to better understand their experiences and learn what is needed to address the challenges they face, whether in the core laboratory, at the point of care or in molecular diagnostics.

"Abbott's Alinity systems are being built from the ground up based on customer insights, using the latest technologies suitable for testing today and in the future," said Dennis Gilbert, Ph.D., vice president, research and development, Diagnostics Products, Abbott. "Whether it's an easy-to-use software interface, running more tests faster or the ability to run any test at any time, our Alinity platforms are designed to include these features and more without any compromise in performance or quality."

The Alinity name is derived from the combination of three key attributes: alignment, innovation and unity. The Alinity suite of products is designed to align with customer goals, provide innovative solutions to address the challenges of today while anticipating those in the future, and work in unity. The systems could help institutions, their laboratorians and their health care providers achieve measurably better performance and help people get the right diagnosis at the right time.

Abbott: Connected Devices Turn Data Into Better Health

Abbott's Robert Ford Joins a Panel Discussing the Potential for Connected Medical Devices to Improve Patient Care and Drive Better Outcomes.

Originally Published by Abbott.

Today's medical devices are creating terabytes of information that gives patients, doctors and health providers real-time insight into someone's vital statistics, heart health and even bloodwork.

But can all this new information really make someone healthier?

Read More Show Less

Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management

State-of-the-art multi-assay test system helps people with diabetes get the HbA1c results they need within three minutes — allowing more time for consultation and care during a single healthcare visit.

Originally Published by Abbott.

Abbott announced the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit.

Read More Show Less

Abbott's Xience Sierra Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan.

Originally Published by Abbott.

Abbott announced that Japan's Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery system, and unique sizes to help doctors treat challenging cases.

XIENCE Sierra was designed to help doctors more easily treat people with difficult-to-treat blockages that involve multiple or totally blocked arteries or complications such as diabetes. Complex cases are increasingly prevalent as people with coronary artery disease are living longer.

"Extensive clinical data and 10 years of real-world experience with the XIENCE family of stents provide doctors with confidence that they are treating their patients with one of the safest stents available," said Chuck Brynelsen, senior vice president of Abbott's vascular business. "National reimbursement of XIENCE Sierra will provide people in Japan with greater access to this life-changing technology that can help them live their best lives."

Coronary artery disease is the most common form of heart disease, which is the second leading cause of death in Japan. National reimbursement in Japan will enable doctors to treat more patients with XIENCE Sierra through the country's health insurance plans. XIENCE Sierra was approved in Japan on April 4, 2018, received CE Mark in Europe late last year, and is under review with the U.S. Food and Drug Administration.

XIENCE has been studied in over 100 clinical trials and in 10 years of global real-world experience. Its safety profile is unprecedented with consistent low rates of stent thrombosis, even in complex cases. More than eight million people worldwide have received a XIENCE stent since its initial regulatory approval.